-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Exegenesis Bio, a gene therapy research and development company, announced that it has successfully completed a round of tens of millions of US dollars in B++ financing.
This round of financing was led by Hillhouse Ventures, followed by Temasek, CPE Yuanfeng and Qingchi Capital.
Shareholders LYFE Capital and Boyuan Capital continued to raise their stakes
.
This round of financing will continue to be used for the rapid clinical advancement of a variety of gene therapy pipelines
Exegenesis Bio, a gene therapy research and development company, announced that it has successfully completed a round of tens of millions of US dollars in B++ financing.
Founded in 2019, Exegenesis Bio is headquartered in Hangzhou, Zhejiang Province.
It is a gene therapy drug research and development company.
The company develops and produces innovative drugs for gene therapy for the Chinese and global markets
.
Dr.
Wu Zhenhua, the founder and CEO of Exegenesis Bio, said that our team has made great progress in the development of gene therapy drugs and platform construction in the past year or so
.
Gene therapy as an important means of future medicine has been developed in Europe and the United States for decades, and many drugs have been approved in many disease fields and have demonstrated unprecedented long-term therapeutic effects
Ms.
Wu Jing, executive general manager of CPE Yuanfeng, said that gene therapy is a new star in the biomedical industry, and it uses innovative mechanisms to solve major unmet clinical needs
.
The two drugs currently on the market in Europe and the United States have verified the pharmaceutical properties and clinical value of gene therapy.
Ms.
Qian Ranting, a PE partner of Qingchi Capital, said that in the past few decades, gene therapy has "innovated" the concept of human treatment of genetic diseases and major diseases, and its development prospects have been widely recognized and fully verified at home and abroad
.
Since its establishment in 2019, Jiain Biological has built a complete gene therapy industry chain from pre-clinical, CMC upstream and downstream processes and clinical stages
